Key Players
Competitive Landscape
Competition divides into cell-cycle oncology portfolios, biomarker-linked PI3K or AKT portfolios, and JAK or TYK2 portfolios across hematology and immune-mediated disease. Suppliers compete through indication breadth and clinical evidence, while monitoring requirements and payer access determine whether an approved product moves into regular use.
Expansion has moved in two directions since 2024. Oncology products are entering earlier-stage or more precisely defined populations, while oral immune-pathway products are gaining new rheumatology and dermatology indications. Bristol Myers Squibb received a new psoriatic-arthritis approval for SOTYKTU in March 2026, and AbbVie received a giant-cell-arteritis approval for RINVOQ in April 2025.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Bristol Myers Squibb received FDA approval for SOTYKTU in active psoriatic arthritis in March 2026. | Adults with psoriatic arthritis need additional oral systemic options. | TYK2 inhibition is expanding beyond plaque psoriasis. | Rheumatology access and indication-led portfolio growth. |
| AbbVie received FDA approval for RINVOQ in giant cell arteritis in April 2025. | Clinicians need oral treatment options for systemic inflammatory disease. | JAK portfolios are extending into additional vasculitis pathways. | Specialist rheumatology use and broader label coverage. |
| Sun Pharma received FDA approval for LEQSELVI in severe alopecia areata in July 2024. | Severe hair-loss disease creates demand for systemic therapy. | Oral JAK inhibitors are entering specialist dermatology pathways. | Dermatology distribution and long-term patient support. |
Novartis, Pfizer, Eli Lilly, AstraZeneca, Roche, Incyte and GSK remain focused on oncology or hematology pathway growth outside the three mapped immune-mediated actions.
Source: Future Market Insights, Non-Tyrosine Kinase Inhibitors Market report, 2026-2036.
Novartis, Pfizer and Eli Lilly cover CDK4/6 treatment. AstraZeneca and Roche cover AKT or PI3K pathways. Bristol Myers Squibb, Incyte, AbbVie, GSK and Sun Pharma extend competition into JAK or TYK2 applications.
Which companies lead CDK4/6 treatment?
Novartis, Pfizer and Eli Lilly have regulator-backed CDK4/6 products through ribociclib, palbociclib and abemaciclib. Their competitive positions depend on labeled settings and evidence for use with endocrine therapy.
Which companies connect treatment to PIK3CA or PTEN status?
Roche and Genentech connect inavolisib use to PIK3CA-mutated breast cancer, while AstraZeneca connects capivasertib regimens to AKT-pathway alterations in breast cancer and PTEN deficiency in prostate cancer.
Which companies serve immune-mediated applications?
Bristol Myers Squibb, AbbVie and Sun Pharma serve psoriasis, psoriatic arthritis, giant cell arteritis or severe alopecia through oral TYK2 or JAK products. Pfizer and Eli Lilly also maintain JAK portfolios across inflammatory disease.
Which companies serve hematology pathways?
Incyte serves myelofibrosis and related hematology settings through ruxolitinib, while GSK serves adults with myelofibrosis and anemia through momelotinib. Hospital monitoring and blood-count review remain important to both routes.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Novartis AG | Oncology | Ribociclib provides an oral CDK4/6 route across advanced and high-risk early breast cancer. |
| Pfizer Inc. | Oncology and immunology | Palbociclib supports CDK4/6 treatment, while tofacitinib provides a JAK route across inflammatory indications. |
| Eli Lilly and Company | Oncology and immunology | Abemaciclib supports CDK4/6 treatment, while baricitinib provides a JAK pathway in immune-mediated disease. |
| AstraZeneca PLC | Biomarker-led oncology | Capivasertib provides an oral AKT-inhibitor route linked to defined breast and prostate cancer populations. |
| Roche Holding AG | Biomarker-led oncology | Inavolisib through Genentech provides an oral PI3K route for PIK3CA-mutated breast cancer. |
| Bristol Myers Squibb | Immunology | Deucravacitinib provides an oral TYK2 route in plaque psoriasis and active psoriatic arthritis. |
| Incyte Corporation | Hematology | Ruxolitinib provides JAK1/JAK2 treatment across myelofibrosis, polycythemia vera and graft-versus-host disease. |
| AbbVie Inc. | Immunology | Upadacitinib provides an oral JAK route across rheumatology, gastroenterology and dermatology indications. |
| GSK plc | Hematology | Momelotinib provides an oral JAK1/JAK2 and ACVR1 route for myelofibrosis in adults with anemia. |
| Sun Pharmaceutical Industries Ltd. | Dermatology | Deuruxolitinib provides an oral JAK route for adults with severe alopecia areata. |
Research Methodology
The companies here show how competition is structured rather than ranking corporate scale or total revenue. Inclusion requires official evidence of an approved product within the listed pathway classes or an adjacent class retained in the market taxonomy. Regulator notices, prescribing information and official company announcements establish current indications and operating scope. Pipeline claims remain separate from approved commercial products, while application ratings refer only to the public evidence reviewed for this article. Segment shares are FMI estimates for 2026 and are kept separate from supplier positioning evidence.
